Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00210) | |||||
---|---|---|---|---|---|
Name |
Dolutegravir
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; Tivicay; GSK 1349572; Dolutegravir (GSK1349572); GSK-1349572; S-349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; DKO1W9H7M1; 1051375-16-6 (free); Tivicay (TN); S-GSK1349572; Dolutegravir [USAN:INN]; Soltegravir; HSDB 8152; Dolutegravir (USAN); (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide; SCHEMBL82071; MLS006011137; GTPL7365; QCR-34; CHEMBL1229211; DTXSID90909356; C20H19F2N3O5; AOB87150; EX-A1695; methyl-9,12-dioxo-4-oxa-1,8-; ABP000915; BDBM50062551; MFCD20488027; ZINC58581064; AKOS025396657; S/GSK-1349572; BCP9000620; CCG-268876; CS-0454; DB08930; PB33506; NCGC00346629-01; NCGC00346629-02; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; AC-28371; AS-75277; HY-13238; SMR004702915; AB0033823; S/GSK1349572,GSK1349572; D10066; Q-4931; Q937224; J-501471; diazatricyclo[8.4.0.0?,?]tetradeca-10,13-diene-13-; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1 ,3]oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide; N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboximidic acid
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Human immunodeficiency virus infection | ICD-11: 1C60 | [1] | ||
PubChem CID | |||||
Formula |
C20H19F2N3O5
|
||||
Canonical SMILES |
C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
|
||||
InChI |
1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
|
||||
InChIKey |
RHWKPHLQXYSBKR-BMIGLBTASA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=54726191"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 419.4 | Topological Polar Surface Area | 99.2 | |
XlogP | 2.4 | Complexity | 829 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 3 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Dolutegravir 25 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide yellow; Talc; Titanium dioxide; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycols; Povidones; Sodium starch glycolate type a corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | ViiV Healthcare Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Dolutegravir 50 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide yellow; Talc; Titanium dioxide; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycols; Povidones; Sodium starch glycolate type a corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | RemedyRepack; ViiV Healthcare Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Dolutegravir 10 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Talc; Titanium dioxide; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycols; Povidones; Sodium starch glycolate type a corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | ViiV Healthcare Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Dolutegravir Sodium eq 5mg base tablet for suspension | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium Sulfate Dihydrate; Crospovidone; Mannitol; Microcrystalline Cellulose; Povidone K29/32; Silicified Microcrystalline Cellulose; Sodium Starch Glycolate; Strawberry Cream Flavor; Sucralose; Sodium Stearyl Fumarate; Hypromellose; Polyethylene Glycol; Titanium Dioxide
|
|||||
Dosage Form | Tablet For Suspension | |||||
Company | Viiv Hlthcare | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sucralose | DIG Info | Carbonic anhydrase II (Ki = 300 nM) | [5] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [4] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
Dolutegravir Sodium eq 50mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D-Mannitol; Microcrystalline Cellulose; Povidone K29/32; Sodium Starch Glycolate; And Sodium Stearyl Fumarate; Macrogol/Peg; Polyvinyl Alcohol-Part Hydrolyzed; Talc; Titanium Dioxide; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Viiv Hlthcare | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [4] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
Dolutegravir Sodium eq 25mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D-Mannitol; Microcrystalline Cellulose; Povidone K29/32; Sodium Starch Glycolate; Sodium Stearyl Fumarate; Macrogol/Peg; Polyvinyl Alcohol-Part Hydrolyzed; Talc; Titanium Dioxide; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Viiv Hlthcare | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [4] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
Dolutegravir Sodium eq 10mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D-Mannitol; Microcrystalline Cellulose; Povidone K29/32; Sodium Starch Glycolate; And Sodium Stearyl Fumarate; Macrogol/Peg; Polyvinyl Alcohol-Part Hydrolyzed; Talc; Titanium Dioxide
|
|||||
Dosage Form | Tablet | |||||
Company | Viiv Hlthcare | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [4] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.